Anicetti Vincent R 4
4 · Coherus BioSciences, Inc. · Filed Dec 21, 2020
Insider Transaction Report
Form 4
Anicetti Vincent R
Chief, Quality & Compliance
Transactions
- Exercise/Conversion
Common Stock
2020-12-17$2.50/sh+2,500$6,251→ 35,069 total - Sale
Common Stock
2020-12-17$17.51/sh−2,500$43,780→ 32,569 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-17−2,500→ 4,988 totalExercise: $2.50Exp: 2024-06-30→ Common Stock (2,500 underlying)
Footnotes (4)
- [F1]Includes 31,250 restricted stock units.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- [F3]The transaction was executed in multiple trades in prices ranging from $17.41 to $17.68, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- [F4]All of the shares underlying this option are vested and exercisable as of the date hereof.